

epkinly[®]
 epcoritamab-bysp
 SUBCUTANEOUS INJECTION 4mg | 48mg

Care Partner

Guide to **EPKINLY**

Approved to treat adults with **diffuse large B-cell lymphoma (DLBCL)** that has returned or that didn't respond after 2 or more prior treatments



Actor portrayals.

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or life-threatening.
- **Neurologic problems** that can be life-threatening and lead to death.
- **Infections and Low blood cell counts.**

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).

Table of contents

What's
inside

Your role as a Care Partner.....	3
Helping with treatment decisions.....	5
About EPKINLY	6
Communicating with your loved one	12
Support and resources	16
Important contact information.....	18

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).



Supporting someone you care about

As a Care Partner, you are an integral part of your loved one's healthcare team. In this role, you may help with decision-making along with providing emotional, medical, or logistical support.

In recognizing that you play an important role, we are dedicated to helping you support yourself as you care for your loved one throughout their treatment with EPKINLY.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).


epcoritamab-bysp[®]
SUBCUTANEOUS INJECTION 4mg/148mg

Your role as a Care Partner

Some responsibilities you may take on during your loved one's treatment:



Decision-making

Researching clinical trials and treatment options, helping to consider treatment choices, and being an advocate for your loved one



Emotional

Encouraging your loved one to share their feelings and helping them feel supported



Medical

Helping watch for potential side effects, attending appointments, and ensuring they have what they need throughout their treatments



Logistical

Scheduling and driving them to appointments, running errands, and assisting with daily needs

Tip: Take time with your loved one to set clear expectations about what responsibilities you may be taking on during their treatment journey.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).

Helping to make treatment decisions

As a Care Partner, you can be an advocate for your loved one by working with the healthcare team to decide on a treatment plan and supporting your loved one through the treatment process. Here are some steps that may help:



1 Gather information

Try connecting with your loved one's healthcare team, other Care Partners, or using online resources such as cancer.gov to research clinical trials and learn from others who have experience with DLBCL.

2 Understand the goals of your loved one and their healthcare team

What is important as you both are considering the next treatment option?

3 Consider potential risks and benefits of therapies

Use your understanding of the information you've learned to weigh each option.

4 Consider personal preferences and goals of treatment

Assess how each option fits in with your loved one's life.

5 Make a decision together with your loved one and their healthcare team

When everyone agrees on a plan, it can make for a smoother and potentially less frustrating treatment experience.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).


Remission is possible

EPKINLY delivers powerful efficacy that can transform uncertainty into hope

The goal of EPKINLY is to help patients achieve long-term remission. Learn about the results that were seen in the clinical study with EPKINLY.

EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY.

In the clinical study:



SELECT IMPORTANT SAFETY INFORMATION

Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or life-threatening. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. Your first full dose will be given on day 15 of your first cycle of treatment and you should be hospitalized for 24 hours after due to the risk of CRS and neurologic problems. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
- **Neurologic problems** that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).

epkinly[®]
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/148mg



~6
weeks

Patients who achieved complete or partial remission **started seeing results in as few as 6 weeks** (median* of 1.4 months; time varied from 1 to 8.4 months).

How was EPKINLY studied?

EPKINLY was studied in 148 patients with DLBCL who had 2 or more treatments and whose cancer returned or did not respond.

Patients had been through a median* of 3 different types of treatments (range of prior treatments was 2 to 11), such as chemotherapy, immunotherapy (uses your body's immune system to help fight cancer), stem cell transplant, and CAR T therapy (chimeric antigen receptor T cell).

*The median is the number that is exactly in the middle of the range seen in the study.

SELECT IMPORTANT SAFETY INFORMATION

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. **These may be symptoms of CRS or neurologic problems.** If you have any symptoms that impair consciousness, **do not** drive or use heavy machinery or do other dangerous activities until your symptoms go away.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).


epcoritamab-bysp[®]
SUBCUTANEOUS INJECTION 4mg/148mg

Unlike an infusion that may take time to administer, EPKINLY is given as an injection

Your loved one may be given treatment at a location that is able to administer EPKINLY, such as their oncologist's office or a nearby outpatient center.

EPKINLY Dosing Schedule:



To increase tolerability and help limit the potential for and severity of CRS, EPKINLY uses a “step-up” dosing schedule

During the first 2 weeks of treatment, your loved one will receive smaller “step-up” doses than the doses they will receive in week 3 and for the rest of their treatment.

- Before and for 3 days after each dose of EPKINLY in their first 4 weeks of treatment, they will receive other medicines to help reduce their risk of CRS. Their healthcare provider will decide if they need to receive medicine to help reduce their risk of CRS in later doses of EPKINLY
- The healthcare provider will discuss with them the need to be hospitalized for 24 hours after their first full dose of EPKINLY (week 3/3rd dose) due to the risk of CRS and neurologic problems
- They may have side effects during treatment. Their healthcare provider will monitor them for symptoms of CRS, neurologic problems, infections, and low blood cell counts. Their treatment may be temporarily or completely stopped if they develop certain side effects
- If their dose of EPKINLY is delayed for any reason, they may need to repeat the step-up dosing schedule

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).



Ongoing treatment with EPKINLY may help ensure the medicine keeps working in your body to help you maintain remission

- Patients will receive EPKINLY for as long as their healthcare provider finds it is working for them and their side effects are manageable
- Your loved one's healthcare provider may delay or completely stop treatment with EPKINLY if certain side effects are experienced

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause other serious side effects, including:

- **Infections** that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell.
- **Low blood cell counts**, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).


epcoritamab-bysp[®]
SUBCUTANEOUS INJECTION 4mg/148mg

Important Safety Information

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

IMPORTANT SAFETY INFORMATION Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or life-threatening. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. Your first full dose of EPKINLY will be given on day 15 of your first cycle of treatment and you should be hospitalized for 24 hours after due to the risk of CRS and neurologic problems. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
- **Neurologic problems** that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or

lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. **These may be symptoms of CRS or neurologic problems.** If you have any symptoms that impair consciousness, **do not** drive or use heavy machinery or do other dangerous activities until your symptoms go away.

EPKINLY can cause other serious side effects, including:

- **Infections** that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell.
- **Low blood cell counts**, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Please see additional Important Safety Information on page 11.
Please see [Medication Guide](#).

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/148mg

Important Safety Information (cont'd)

Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. **If you are a female who can become pregnant**, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

The most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. **The most common severe abnormal laboratory test results** include decreased white blood cells, decreased red blood cells, and decreased platelets.

These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on page 10. Please see [Medication Guide](#).





Supporting your loved one

As a Care Partner, you're an advocate for your loved one. You work with the healthcare team to decide on a treatment plan and help your loved one through it all.

Some suggestions you may find beneficial are:

Before appointments

Preparing for treatment can be stressful, but you can help by knowing your loved one's medical history before going to appointments.

During appointments

You can help at appointments by being prepared with questions, taking notes during the conversation, and keeping track of upcoming appointments.

After appointments

After appointments with the healthcare team, it's important to watch your loved one for any side effects they may have.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).

Communicating with your loved one

When someone you love is going through treatment, it's easy to deprioritize your own needs. Having honest conversations about how you're feeling, how you can provide support, and what you need in order to avoid burnout can strengthen a relationship and help you provide the best care possible.

Consider these tips:

- Be available to talk, but don't force anything
- Remember that people communicate in different ways
- Take cues from the person you're caring for
- Be realistic and flexible about what you hope to discuss and where you can find agreement
- Respect your loved one's privacy or their need to be alone

Care Partner & patient discussion guide

It's important that Care Partners and their loved ones are on the same page and are able to express their needs. Use these statements to help guide you when you are talking with your loved one about their treatment.

When you say _____, it makes me feel _____.

If I am feeling _____, how can we work through that together?

If we need more support, we can bring in _____ as an additional Care Partner.

I can _____ to best respect your independence during treatment.

The best time to check in with me about how I'm feeling is _____.

During stressful times, I can _____ to make things easier for both of us.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).

Taking care of yourself

When caring for someone with cancer, there can be high and low periods. It can be common to overlook your own needs. However, it is extremely important to take care of your own well-being, too.

Understanding the possibility of burnout

Burnout is a state of physical, emotional, and mental exhaustion that can happen while you are caring for someone else.

What are signs of Care Partner burnout?

- Emotional and physical exhaustion
- Changes in appetite and/or weight
- Inability to concentrate
- Getting sick more often
- Irritability, frustration, or anger toward others
- Withdrawal from friends, family, and other loved ones; loss of interest in activities previously enjoyed
- Feeling hopeless and helpless

Ask for help

Avoid taking on too much yourself. Don't be afraid to reach out to someone for help with:

- Chores, such as cooking, cleaning, shopping, or yard work
- Driving your loved one to appointments or picking up medicines
- Being the contact person to keep others updated

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).

Take the time you need

A little “me time” goes a long way when you’re a Care Partner.

Engage in self-care

It is important to remember that even though you are part of a team, you need to take time for yourself. Make a plan to:

- Avoid skipping personal appointments
- Make sure you eat well-balanced meals throughout the day
- Maintain a healthy sleep schedule
- Exercise, which can also improve your mood

Manage stress

You are important, and neglecting your needs can contribute to stress. Your mental well-being is just as important as your physical health. Consider these stress reducers:

- Talk to a trusted friend or relative
- Go for a walk
- Meditate

Care Partner community

Organizations within your community may offer services and support. Explore joining groups that can connect you with others who are in a similar situation and can lend a hand when you’re in need.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).

MyNavCare is here to support you



With *MyNavCare*, you and your loved one can receive personalized support throughout the treatment journey from a dedicated team that cares



A partner on the treatment journey

Your loved one's healthcare provider is your main source for treatment information. With *MyNavCare*, you gain access to additional resources and medication information.

- Dedicated support throughout your loved one's treatment
- Information about treatment access and financial support*
- Insight into independent organizations that may provide additional assistance
- Additional tools and resources that may help along the way



Financial assistance for eligible patients

MyNavCare may be able to help uninsured or underinsured patients receive financial assistance and information. This includes:

- Co-pay assistance program for commercially insured patients*
- Independent patient assistant foundation information†
- Genmab Patient Assistance Program



Ongoing personalized support

Your **Patient Engagement Liaison**‡ provides ongoing support throughout treatment. They're dedicated to you, helping to:

- Provide information about your loved one's condition
- Connect you to third-party organizations that may be able to help
- Offer resources for you and your loved one

*Based on eligibility requirements and Terms and Conditions.

†Eligibility criteria are determined by each independent third-party foundation. *MyNavCare* does not determine eligibility and cannot guarantee foundations will offer assistance.

‡*MyNavCare* Patient Engagement Liaisons are part of the *MyNavCare* Patient Support Program and do not provide medical advice or work under the direction of the prescribing healthcare providers. They are trained to direct patients to speak with their healthcare provider about any treatment-related questions.

Contact a *MyNavCare* Support Specialist by calling
1-866-NAV-CARI (1-866-628-2271), Monday-Friday, 8 AM - 8 PM ET.
You can also scan the QR code or visit www.MyNavCare.com to learn more.



Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).



Resources to support you and your loved one

Here are organizations that can help you and your loved one connect with others, and provide information and resources throughout treatment.



CancerCare

www.cancer.org | 800-813-HOPE (4673)



American Cancer Society

www.cancer.org | 800-227-2345



Lymphoma Research Foundation

www.lymphoma.org | 800-500-9976



The Leukemia & Lymphoma Society

www.lls.org | 800-955-4572



Family Reach

www.familyreach.org | 973-394-1411 ext. 1



Follicular Lymphoma Foundation

www.theflf.org | info@theflf.org

There are many available resources that may be helpful to patients, families, and Care Partners dealing with cancer. The above resources are not controlled, owned, or endorsed by Genmab/AbbVie, and Genmab and AbbVie are not responsible for their content.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).

Important contact information

Write down contact information for members of your loved one's healthcare team and other emergency contacts for quick and easy access.

Doctor

Name: _____

Phone number: _____

Office address: _____

Nurses

Name: _____

Phone number: _____

Office address: _____

Name: _____

Phone number: _____

Office address: _____

Pharmacy

Name: _____

Phone number: _____

Pharmacy address: _____

Emergency Contacts

Name: _____

Phone number: _____

Name: _____

Phone number: _____

If you notice any unexpected side effects or unusual symptoms with your loved one, reach out to their healthcare team right away.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).



Partnering together every step of the way



Scan the QR code or visit EPKINLY.com/DLBCL for more information.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#).



Distributed and marketed by Genmab US Inc. 777 Scudders Mill Road, Plainsboro, NJ 08536.
Distributed and marketed by AbbVie Inc. 1 North Waukegan Road, North Chicago, IL 60064.
EPKINLY and MyNavCare Patient Support are trademarks of Genmab A/S.
All other trademarks and registered trademarks are the property of their respective owners.
©2024 Genmab A/S and AbbVie. All rights reserved.
09/2024 COM-US-EPK-0000976


epcoritamab-bysp[®]
SUBCUTANEOUS INJECTION 4mg/48mg